Charles River Laboratories says it is “seriously pursuing” geographical expansion of its recently acquired HemaCare business as it assesses further opportunities in the cell and gene therapy space. In December last year, contract research organization (CRO) Charles River picked up HemaCare for $380 million, bolstering its cell therapy services portfolio. The firm predicted the acquisition would add at least $50 million to its 2020 consolidated revenue and expects revenue growth for the business to substantially increase over the next five…